Sleep Respiratory Disorders Evaluation in Sickle Cell Disease Children

NCT ID: NCT01565954

Last Updated: 2019-03-13

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 62 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-01-31
• Study Completion Date: 2018-08-31

Brief Summary

In Sickle cell disease children, sleep respiratory abnormalities are risk factors for vaso-occlusive complications, as well as cerebral vasculopathy.

A 18 months follow-up children with sickle cell disease evaluating sleep respiratory problems frequency and etiology, as well as their influence on sickle cell disease complications.

Detailed Description

• Inclusion visit with physical examination. A 2.9 ml blood sample will be necessary, if not done within the framework of care within 6 months for: CBC (Cell Blood Count), reticulocytes counts (1.2 ml of blood), liver enzymes, electrolytes, urea, creatininemia (1,2 ml of blood) and fetal hemoglobin (0.5 ml of blood). - A complete standardized examination including nasopharynx endoscopy, if not yet done in usual care, to identified upper airway obstruction
• A standardized pneumology evaluation to identified obstructive lung symptomatology
• An ambulatory polysomnography will be performed within days following inclusion, during sleep and will allow electroencephalogram recording, oculomotricity, muscles (mentalis muscles and tibialis anterior) movements, electrocardiogram and respiratory activity recording.

The steering committee will classify the children in three populations based on their exam results:

• Group 1: no abnormality in polysomnography
• Group 2: obstructive sleep-related disorder
• Group 3: isolated sleep hypoxemia for group3, patients will have a new ambulatory polysomnography.

Conditions

Sickle Cell Disease; Respiration Disorders

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Sickle cell disease children with either sickle cell anemia, compound heterozygozity SB0-thalassemia, or SDPunjab,
• no prior transfusion program within 3 months,
• no prior treatment with hydroxycarbamide within 3 months,
• Aged 2 to 6 years,
• Parents or tutors signed informed consent,
• Prior physical examination,
• Social security insurance.

Exclusion Criteria

• Encephalopathy
• Other disease that could interfere with protocol exams realization
• Nitrous oxide analgesia contre-indication
• Conventional hospitalization in the past 3 weeks

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 6 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Malika BENKERROU, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Locations

Assistance Publique - Hôpitaux de Paris

Paris, , France

Countries

France

Other Identifiers

2011-005029-31

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

P110102

Identifier Type: -

Identifier Source: org_study_id